Company intelligence / Profile preview
Ganzhou Hemay Pharmaceutical Co., Ltd.
Ganzhou City, Jiangxi Province, Chinahemay.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple clinical-stage drug candidates with Mufemilast (PDE4 inhibitor) at NDA/BLA stage for plaque psoriasis, Sacibertinib (HER2 antagonist) in Phase 3 for breast cancer, Hemay007 (TNF-α inhibitor) in Phase 2 for rheumatoid arthritis, and two Phase 1 candidates (Hemay181 and Hemay-020)
- Therapeutic areas
- OncologyPulmonologyImmunologyDermatologyRheumatologyGastroenterology
- Modalities
- Small molecule drugsBispecific antibodies (BsAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Wuhan Institute of Virology, Chinese Academy of Sciences (WIV)
Beyond the preview
Go deeper on Ganzhou Hemay Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganzhou Hemay Pharmaceutical Co., Ltd..